Novo Nordisk Cuts Wegovy Price in South Africa Again as GLP-1 Global Pricing War Heats Up
By FieldPulse Editorial · March 25, 2026
Tags: GLP-1, Drug Pricing
Novo Nordisk has slashed Wegovy prices in South Africa for the second time, with the lowest injected dose now at ~$110 — a 60% reduction. The move reflects intensifying competition from Eli Lilly's Mounjaro in emerging markets.
Novo Nordisk has cut the price of Wegovy in South Africa for the second time, acknowledging that its original pricing structure was incompatible with the realities of the market.
The reductions, announced March 25, are substantial: the lowest injected dose is now priced at approximately $110, down 60 percent, while the highest dose has been reduced by 27 percent to roughly $221.
The company was direct about the motivation.
Novo said its original pricing was "not conducive for the South African market" — an unusually candid admission that reflects the broader challenge GLP-1 manufacturers face as they push beyond high-income Western markets where insurance reimbursement and high out-of-pocket tolerance underpin premium pricing strategies.
The competitive context is critical.
Eli Lilly's Mounjaro (tirzepatide) was cited as a key factor in the pricing pressure.
Lilly has been aggressively expanding into emerging markets, and tirzepatide's clinical profile — including weight loss data that compares favorably to semaglutide — gives it credibility as a commercial competitor even outside the United States and Europe.
Novo's decision to move on price rather than cede market access is a sign of how seriously the company views Lilly's global ambitions.
Novo also confirmed plans to introduce oral Wegovy (semaglutide) in South Africa, adding a formulation option that could further expand the addressable patient population in markets where injectable GLP-1 adoption has faced cultural or logistical barriers.
For reps in the metabolic, primary care, or endocrinology space, this story is a signal of what the GLP-1 competitive environment is becoming globally — and potentially domestically over time.
As payer and government pressure on GLP-1 pricing intensifies in the U.S.
and abroad, understanding how Novo and Lilly are positioning their products across different market segments will be increasingly relevant to competitive selling conversations.
The days of GLP-1 pricing as a relat.
Source: https://wkzo.com/2026/03/25/novo-nordisk-cuts-wegovy-price-in-south-africa-for-second-time/